Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhBMP-2 for Early Bone Formation in Osteoporotic TLIF
NCT05911477Unknown
- Sponsor
- Xijing Hospital
- Start
- Jul 2023
- Primary completion
- Dec 2023
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Randomised, open-label trial of dibotermin alfa (2 arms), sponsored by Xijing Hospital. Primary endpoints: Fusion rate at 6 months and Fusion rate at 3 months. Status: unknown.
02
Drugs
dibotermin alfa
Beyond the preview
Go deeper on NCT05911477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05911477.